Muddasir Qureshi

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Increased incidence of deep venous thrombosis in ALS
    M Muddasir Qureshi
    Neurology Clinical Trials Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA 02129, USA
    Neurology 68:76-7. 2007
  2. ncbi Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis
    Muddasir Qureshi
    Neurology Clinical Trials Unit, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA
    Amyotroph Lateral Scler 9:369-74. 2008
  3. ncbi Lyme disease serology in amyotrophic lateral sclerosis
    Muddasir Qureshi
    Neurology Clinical Trials Unit, Massachusetts General Hospital, Harvard Medical School, 13th Street, Building 149, Room 2274, Charlestown, Massachusetts 02129, USA
    Muscle Nerve 40:626-8. 2009
  4. ncbi The natural history of ALS is changing: improved survival
    Muddasir Qureshi
    Neurology Clinical Trials Unit, Massachusetts General Hospital, Harvard Medical School, 13th Street, Boston, MA 02129, USA
    Amyotroph Lateral Scler 10:324-31. 2009
  5. ncbi Serum ferritin and metal levels as risk factors for amyotrophic lateral sclerosis
    Muddasir Qureshi
    Neurology Clinical Trials Unit Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA
    Open Neurol J 2:51-4. 2008

Detail Information

Publications5

  1. ncbi Increased incidence of deep venous thrombosis in ALS
    M Muddasir Qureshi
    Neurology Clinical Trials Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA 02129, USA
    Neurology 68:76-7. 2007
  2. ncbi Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis
    Muddasir Qureshi
    Neurology Clinical Trials Unit, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA
    Amyotroph Lateral Scler 9:369-74. 2008
    ..035). We conclude that aspirin or NSAID use may shorten survival in ALS, while calcium use may prolong survival. Our results support a need to further explore the role of neuroinflammation in the pathogenesis of ALS...
  3. ncbi Lyme disease serology in amyotrophic lateral sclerosis
    Muddasir Qureshi
    Neurology Clinical Trials Unit, Massachusetts General Hospital, Harvard Medical School, 13th Street, Building 149, Room 2274, Charlestown, Massachusetts 02129, USA
    Muscle Nerve 40:626-8. 2009
    ..97%) had confirmed past immunoreactive infection. Two of these patients received ceftriaxone for 1 month without clinical improvement. Lyme disease was rare in 414 patients with ALS and is not likely to be causative...
  4. ncbi The natural history of ALS is changing: improved survival
    Muddasir Qureshi
    Neurology Clinical Trials Unit, Massachusetts General Hospital, Harvard Medical School, 13th Street, Boston, MA 02129, USA
    Amyotroph Lateral Scler 10:324-31. 2009
    ..However, the decline in measures of function appears unchanged since then. These changes in natural history reflect improvements in symptomatic care of ALS...
  5. ncbi Serum ferritin and metal levels as risk factors for amyotrophic lateral sclerosis
    Muddasir Qureshi
    Neurology Clinical Trials Unit Massachusetts General Hospital, Harvard Medical School, Charlestown, MA, 02129, USA
    Open Neurol J 2:51-4. 2008
    ..We conclude that twenty-four hour urine or blood testing for metals is not warranted as part of the evaluation of ALS. Elevated levels of serum ferritin in ALS population could reflect an underlying perturbation in iron metabolism...